Alnylam Pharmaceuticals
ALNY
#815
Rank
S$40.38 B
Marketcap
S$301.79
Share price
0.23%
Change (1 day)
-47.40%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): S$4.89

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$4.82. In 2025 the company made an earnings per share (EPS) of S$2.29.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$4.89113.23%
2025S$2.29
2023S-$4.49-62%
2022S-$11.8229.03%
2021S-$9.16-3.36%
2020S-$9.48-8.48%
2019S-$10.367.67%
2018S-$9.6239.74%
2017S-$6.8912.94%
2016S-$6.1038.84%
2015S-$4.39-32.88%
2014S-$6.54259.44%
2013S-$1.82-31.25%
2012S-$2.65

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$8.94 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$3.26-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$54.13 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$0.73-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.93-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.34-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$1.74-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S$1.03-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA